These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 38474255)

  • 1. Acute and Chronic Exposure to Linagliptin, a Selective Inhibitor of Dipeptidyl Peptidase-4 (DPP-4), Has an Effect on Dopamine, Serotonin and Noradrenaline Level in the Striatum and Hippocampus of Rats.
    Łupina M; Wąsik A; Baranowska-Bosiacka I; Tarnowski M; Słowik T; Listos P; Kotlińska J; Kosik-Bogacka D; Gutowska I; Listos J
    Int J Mol Sci; 2024 Mar; 25(5):. PubMed ID: 38474255
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of renal dipeptidyl peptidase-4 in kidney disease: renal effects of dipeptidyl peptidase-4 inhibitors with a focus on linagliptin.
    Kanasaki K
    Clin Sci (Lond); 2018 Feb; 132(4):489-507. PubMed ID: 29491123
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of linagliptin, a selective dipeptidyl peptidase-4 inhibitor, in the morphine rewarding effects in rats.
    Łupina M; Talarek S; Kotlińska J; Gibuła-Tarłowska E; Listos P; Listos J
    Neurochem Int; 2020 Feb; 133():104616. PubMed ID: 31809774
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dipeptidyl peptidase-4 inhibitors can inhibit angiotensin converting enzyme.
    Abouelkheir M; El-Metwally TH
    Eur J Pharmacol; 2019 Nov; 862():172638. PubMed ID: 31491403
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The dipeptidyl peptidase inhibitor linagliptin and the angiotensin II receptor blocker telmisartan show renal benefit by different pathways in rats with 5/6 nephrectomy.
    Tsuprykov O; Ando R; Reichetzeder C; von Websky K; Antonenko V; Sharkovska Y; Chaykovska L; Rahnenführer J; Hasan AA; Tammen H; Alter M; Klein T; Ueda S; Yamagishi SI; Okuda S; Hocher B
    Kidney Int; 2016 May; 89(5):1049-1061. PubMed ID: 27083282
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A dipeptidyl peptidase-4 (DPP-4) inhibitor, linagliptin, attenuates cardiac dysfunction after myocardial infarction independently of DPP-4.
    Yamaguchi T; Watanabe A; Tanaka M; Shiota M; Osada-Oka M; Sano S; Yoshiyama M; Miura K; Kitajima S; Matsunaga S; Tomita S; Iwao H; Izumi Y
    J Pharmacol Sci; 2019 Feb; 139(2):112-119. PubMed ID: 30638989
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differences in kidney-specific DPP-4 inhibition by linagliptin and sitagliptin.
    Luippold G; Mark M; Klein T; Amann K; Daniel C
    Diabetes Res Clin Pract; 2018 Sep; 143():199-203. PubMed ID: 30031047
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of DPP-4 inhibitors on the heart in a rat model of uremic cardiomyopathy.
    Chaykovska L; von Websky K; Rahnenführer J; Alter M; Heiden S; Fuchs H; Runge F; Klein T; Hocher B
    PLoS One; 2011; 6(11):e27861. PubMed ID: 22125632
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanisms of GLP-1 receptor-independent renoprotective effects of the dipeptidyl peptidase type 4 inhibitor linagliptin in GLP-1 receptor knockout mice with 5/6 nephrectomy.
    Hasan AA; von Websky K; Reichetzeder C; Tsuprykov O; Gaballa MMS; Guo J; Zeng S; Delić D; Tammen H; Klein T; Kleuser B; Hocher B
    Kidney Int; 2019 Jun; 95(6):1373-1388. PubMed ID: 30979564
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of DPP-4 inhibition to improve functional outcome after stroke is mediated by the SDF-1α/CXCR4 pathway.
    Chiazza F; Tammen H; Pintana H; Lietzau G; Collino M; Nyström T; Klein T; Darsalia V; Patrone C
    Cardiovasc Diabetol; 2018 May; 17(1):60. PubMed ID: 29776406
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DPP-4 Inhibitor Linagliptin Ameliorates Oxidized LDL-Induced THP-1 Macrophage Foam Cell Formation and Inflammation.
    Wang H; Li Y; Zhang X; Xu Z; Zhou J; Shang W
    Drug Des Devel Ther; 2020; 14():3929-3940. PubMed ID: 33061298
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of inflammation-mediated DPP-4 expression by linagliptin increases M2 macrophages in atherosclerotic lesions.
    Nishida S; Matsumura T; Senokuchi T; Murakami-Nishida S; Ishii N; Morita Y; Yagi Y; Motoshima H; Kondo T; Araki E
    Biochem Biophys Res Commun; 2020 Mar; 524(1):8-15. PubMed ID: 31964532
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Binding to dipeptidyl peptidase-4 determines the disposition of linagliptin (BI 1356)--investigations in DPP-4 deficient and wildtype rats.
    Retlich S; Withopf B; Greischel A; Staab A; Jaehde U; Fuchs H
    Biopharm Drug Dispos; 2009 Nov; 30(8):422-36. PubMed ID: 19771584
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The DPP-4 inhibitor linagliptin restores β-cell function and survival in human isolated islets through GLP-1 stabilization.
    Shah P; Ardestani A; Dharmadhikari G; Laue S; Schumann DM; Kerr-Conte J; Pattou F; Klein T; Maedler K
    J Clin Endocrinol Metab; 2013 Jul; 98(7):E1163-72. PubMed ID: 23633194
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Linagliptin, a DPP-4 inhibitor, ameliorates Aβ (1-42) peptides induced neurodegeneration and brain insulin resistance (BIR) via insulin receptor substrate-1 (IRS-1) in rat model of Alzheimer's disease.
    Siddiqui N; Ali J; Parvez S; Zameer S; Najmi AK; Akhtar M
    Neuropharmacology; 2021 Sep; 195():108662. PubMed ID: 34119519
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Native, Intact Glucagon-Like Peptide 1 Is a Natural Suppressor of Thrombus Growth Under Physiological Flow Conditions.
    Sternkopf M; Nagy M; Baaten CCFMJ; Kuijpers MJE; Tullemans BME; Wirth J; Theelen W; Mastenbroek TG; Lehrke M; Winnerling B; Baerts L; Marx N; De Meester I; Döring Y; Cosemans JMEM; Daiber A; Steven S; Jankowski J; Heemskerk JWM; Noels H
    Arterioscler Thromb Vasc Biol; 2020 Mar; 40(3):e65-e77. PubMed ID: 31893947
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The dipeptidyl peptidase-4 inhibitor linagliptin attenuates inflammation and accelerates epithelialization in wounds of diabetic ob/ob mice.
    Schürmann C; Linke A; Engelmann-Pilger K; Steinmetz C; Mark M; Pfeilschifter J; Klein T; Frank S
    J Pharmacol Exp Ther; 2012 Jul; 342(1):71-80. PubMed ID: 22493041
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of the linagliptin, dipeptidyl peptidase-4 inhibitor, on bone fragility induced by type 2 diabetes mellitus in obese mice.
    Kanda J; Furukawa M; Izumo N; Shimakura T; Yamamoto N; Takahashi HE; Wakabayashi H
    Drug Discov Ther; 2020 Nov; 14(5):218-225. PubMed ID: 33116039
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dipeptidyl peptidase-4 (DPP-4) inhibition with linagliptin reduces western diet-induced myocardial TRAF3IP2 expression, inflammation and fibrosis in female mice.
    Aroor AR; Habibi J; Kandikattu HK; Garro-Kacher M; Barron B; Chen D; Hayden MR; Whaley-Connell A; Bender SB; Klein T; Padilla J; Sowers JR; Chandrasekar B; DeMarco VG
    Cardiovasc Diabetol; 2017 May; 16(1):61. PubMed ID: 28476142
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Linagliptin decreased the tumor progression on glioblastoma model.
    Tsuji S; Kudo U; Hatakeyama R; Shoda K; Nakamura S; Shimazawa M
    Biochem Biophys Res Commun; 2024 Jun; 711():149897. PubMed ID: 38608433
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.